Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3676099 | 0.93 | GRIN1 (0.34) | TSHR | |
| SCHEMBL12499996 | 0.91 | GRIN1 (0.33) | TSHR | |
| SCHEMBL29013944 | 0.69 | GRIN1 (0.36) | TSHR | |
| SCHEMBL7619912 | 0.69 | SLC6A4 (0.30) | — | |
| SCHEMBL7776154 | 0.68 | — | — | |
| SCHEMBL10888167 | 0.68 | — | — | |
| SCHEMBL11164661 | 0.68 | TSHR (0.40) | TSHR | |
| SCHEMBL3027835 | 0.67 | — | — | |
| SCHEMBL23168690 | 0.67 | GRIN1 (0.33) | TSHR | |
| SCHEMBL1627516 | 0.66 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102763254-B | High energy density redox flow device | MASSACHUSETTS INST TECHNOLOGY | 2015-07-08 | — | — | CN | disclosed |
| CN-104701504-A | High energy density redox flow device | MASSACHUSETTS INST TECHNOLOGY | 2015-06-10 | — | — | CN | disclosed |
| CN-102763254-A | High energy density redox flow device | MASSACHUSETTS INST TECHNOLOGY | 2012-10-31 | — | — | CN | disclosed |
| US-6960573-B2 | Vitamin D3 derivative and treating agent for inflammatory respiratory disease using same | TEIJIN LIMITED (JP) | 2005-11-01 | — | — | US | disclosed |
| US-6867313-B2 | Vitamin D3 derivative and treating agent for inflammatory respiratory disease using same | TEIJIN LIMITED (JP) | 2005-03-15 | — | — | US | disclosed |
| US-6689766-B2 | ALSO FOR TREATING MALIGNANT TUMORS, RHEUMATOID ARTHRITIS, OSTEOPOROSIS, DIABETES MELLITUS, HYPERTENSION, ALOPECIA, ACNE, PSORIASIS, DERMATITIS, HYPERCALCEMIA, HYPOPARATHYROIDISM AND METABOLIC DISORDER OF CARTILAGE. | TEIJIN LIMITED (JP) | 2004-02-10 | — | — | US | disclosed |
| US-6548489-B2 | Also for treating malignant tumors, rheumatoid arthritis, osteoporosis, diabetes mellitus, hypertension, alopecia, acne, psoriasis, dermatitis, hypercalcemia, hypoparathyroidism and metabolic disorder of cartilage. | TEIJIN LIMITED (JP) | 2003-04-15 | — | — | US | disclosed |
| US-6531460-B1 | Vitamin D3 derivatives | TEIJIN LIMITED (JP) | 2003-03-11 | — | — | US | disclosed |
| US-20020132799-A1 | Vitamin D3 dervative and treating agent for inflammatory respiratory disease using same | TEIJIN LIMITED | 2002-09-19 | — | — | US | disclosed |
| US-20020103173-A1 | Vitamin D3 derivative and treating agent for inflammatory respiratory disease using same | TEIJIN LIMITED | 2002-08-01 | — | — | US | disclosed |
| US-20020099039-A1 | Vitamin D3 derivative and treating agent for inflammatory respiratory disease using same | TEIJIN LIMITED | 2002-07-25 | — | — | US | disclosed |
| US-20020091109-A1 | Vitamin D3 derivative and treating agent for inflammatory respiratory disease using same | TEIJIN LIMITED | 2002-07-11 | — | — | US | disclosed |
| EP-1123921-A1 | VITAMIN D 3? DERIVATIVES AND REMEDIES FOR INFLAMMATORY RESPIRATORY DISEASES CONTAINING THE SAME | TEIJIN LIMITED (JP) | 2001-08-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020103173-A1 | Vitamin D3 derivative and treating agent for inflammatory respiratory disease using same | CYP24A1, VDR, CYP2R1 | MAPT 4228/4885CYP2C9 1626/4885TSHR 256/4885 |
| US-20020132799-A1 | Vitamin D3 dervative and treating agent for inflammatory respiratory disease using same | CYP24A1, VDR, CYP2R1 | MAPT 4371/4885CYP2C9 2268/4885TSHR 307/4885 |
| US-20020099039-A1 | Vitamin D3 derivative and treating agent for inflammatory respiratory disease using same | CYP24A1, VDR, CYP2R1 | MAPT 4228/4885CYP2C9 1626/4885TSHR 256/4885 |
| US-20020091109-A1 | Vitamin D3 derivative and treating agent for inflammatory respiratory disease using same | CYP24A1, VDR, CYP2R1 | MAPT 4228/4885CYP2C9 1626/4885TSHR 256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.